A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy
Recent reports underscore the unparalleled potential of antisense-oligonucleotide (ASO)-based approaches to ameliorate various pathological conditions. However, in vivo studies validating the effectiveness of a short ASO (<10-mer) in the context of a human disease have not been performed. One dis...
Enregistré dans:
Auteurs principaux: | Jeffrey M Keil (Auteur), Joonbae Seo (Auteur), Matthew D Howell (Auteur), Walter H Hsu (Auteur), Ravindra N Singh (Auteur), Christine J DiDonato (Auteur) |
---|---|
Format: | Livre |
Publié: |
Elsevier,
2014-01-01T00:00:00Z.
|
Sujets: | |
Accès en ligne: | Connect to this object online. |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
par: Haiyan Zhou, et autres
Publié: (2020) -
A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
par: Konstantinos Biliouris, et autres
Publié: (2018) -
Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to Antisense Oligonucleotide Therapy
par: Francesco Catapano, et autres
Publié: (2016) -
A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen
par: Alessio Paris, et autres
Publié: (2023) -
Comment on: "Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy" by Zhou et al.
par: Tai‐Heng Chen
Publié: (2020)